Dr. Markwin Velders, current CEO and co-founder of Myogene Therapeutics BV, started his career as scientist and assistant professor in molecular immunology at Loyola University Chicago. He has over 20 years of business experience at leading positions in biotech, such as CSO at AM-Pharma, Operations Manager and Business Unit Manager at TNO and CEO of SomantiX, developing angiogenesis inhibitors. In 2013 he was involved in spinning out T-Cell Factory from the Dutch Cancer Institute and played a crucial role in its acquisition by Kite Pharma. From 2015 Markwin worked as VP Operations and Managing Director at Kite Pharma. In this period he established the company’s EU headquarters and built the organization from 3 up to 300+ employees. After the company’s acquisition by Gilead, Markwin headed its CAR-T commercial manufacturing site and played a key role in the commercial launch of Kite’s CAR-T therapy in Europe. From 2017 until 2021 he served as Chairman of the Board of HollandBIO. He is Supervisory Board Member at Amarna Therapeutics, and ISA Pharmaceuticals, and advisor to several other biotech companies and VCs in EU, UK and USA.